This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
[212Pb]Pb-DOTAMTATE showed superior tumor-to-kidney uptake ratio compared to other somatostatin receptor-targeting peptides, making it the most promising candidate for targeted alpha therapy of neuroendocrine tumors.
Why it matters
Kidney damage limits how much radioactive peptide therapy can be given. A peptide that concentrates more in tumors and less in kidneys could allow higher, more effective doses.
The numbers in context
Superior tumor-to-kidney AUC ratio for DOTAMTATE; DOTAM chelator had best chelation efficiency and fastest kinetics; compared DOTAMTATE, DOTATATE, JR11, and PSC-PEG2-TOC
How the study worked
Head-to-head preclinical comparison of four SSTR2-targeting peptides labeled with 212Pb. Chelation efficiency, pharmacokinetics, and biodistribution studied in AR42J tumor-bearing animals.
Who was studied
AR42J tumor-bearing animals (neuroendocrine tumor model)
What this study cannot tell us
Animal model only. AR42J xenograft may not represent all human neuroendocrine tumors. 212Pb-specific dosimetry may differ from other radionuclides used clinically (e.g., 177Lu).
Read the original research
Side-by-Side Comparison of the In Vivo Performance of [212Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 66(3), 391-397
Citation
Saidi, Amal; Stallons, Tania A; Wong, Amy G; Schatzmann, Aaron T; Soysal, Ugur; Torgue, Julien J. (2025). Side-by-Side Comparison of the In Vivo Performance of [212Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 66(3), 391-397. https://doi.org/10.2967/jnumed.124.268345